Physician preferences of biomarker testing strategies in newly diagnosed stage IV non-small cell lung cancer patients.

To understand physicians' attitudes and behaviors regarding EGFR testing and retesting strategies in newly diagnosed metastatic non-small cell lung cancer patients. Oncologists and pathologists completed an online, cross-sectional survey. Most oncologists (73.